Oslo, 27. October 2016. Serodus ASA (OAX:SER) announces its results for the third quarter 2016.

Highlights include:

SER150 Diabetic Nephropathy

  • Randomization of patients to cohort 2 is behind schedule. Expected to end enrolment late October.

SER100 Pulmonary Hypertension

  • Orphan Drug Designation granted in US

Finance and Investor Relations

  • Finalized the private placement of MNOK 10
  • Serodus is evaluating and testing a delisting from the Norwegian Stock Exchange among larger shareholders.

Quarterly report is available on http://www.serodus.com/Investor/Reports/Quarterly-reports.

For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information, see www.serodus.com.

Serodus ASA published this content on 27 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 October 2016 06:41:04 UTC.

Original documenthttp://www.serodus.com/News/2016/Q3-2016-Interim-results

Public permalinkhttp://www.publicnow.com/view/D554C488C374463060E61A4FC2337E72706FC474